Literature DB >> 6341484

Quantitative determination in human sera of vaccine-induced antibody to type-specific polysaccharides of group B streptococci using an enzyme-linked immunosorbent assay.

T K Eisenstein, B J De Cueninck, D Resavy, G D Shockman, R B Carey, R M Swenson.   

Abstract

The humoral immune response of human volunteers vaccinated with highly purified type II-or type III-specific polysaccharide of group B streptococci was evaluated using an enzyme-linked immunosorbent assay standardized with quantitative precipitin analysis, a method which permits calculation of the micrograms of specific antibody protein per milliliter of serum, rather than expression of the data as titers. By inhibition studies, the assays were shown to be specific for antibody to the undegraded type II or III polysaccharide antigen. Purity of the antigens and the specificity of the immune response to them were evidenced by an increase in level of antibody only to the type-specific antigen used for immunization. The isotype of the antibody raised in the sera of immunized volunteers was primarily IgG, thus confirming the potential utility of vaccination against group B streptococci using polysaccharide vaccines to induce antibodies which will cross the human placenta.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6341484     DOI: 10.1093/infdis/147.5.847

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

1.  Immunoprophylaxis and immunotherapy of neonatal group B streptococcal infections.

Authors:  S P Gotoff
Journal:  Infection       Date:  1985       Impact factor: 3.553

2.  Immunomodulation of the antibody response to lipopolysaccharide in C3H/HeJ mice by complexing with heterologous ribosomes.

Authors:  M Phillips; T K Eisenstein; J Meissler
Journal:  Infect Immun       Date:  1985-04       Impact factor: 3.441

3.  Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid.

Authors:  T Lagergard; J Shiloach; J B Robbins; R Schneerson
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

4.  Evaluation of the antibody response in pigs vaccinated against Streptococcus suis capsular type 2 using a double-antibody sandwich enzyme-linked immunosorbent assay.

Authors:  C Blouin; R Higgins; M Gottschalk; J Simard
Journal:  Can J Vet Res       Date:  1994-01       Impact factor: 1.310

5.  Immunoprophylaxis and immunotherapy of neonatal group B streptococcal infections.

Authors:  S P Gotoff
Journal:  Infection       Date:  1984 Mar-Apr       Impact factor: 3.553

6.  Immunoglobulin G and M composition of naturally occurring antibody to type III group B streptococci.

Authors:  B F Anthony; N F Concepcion; C A Wass; D C Heiner
Journal:  Infect Immun       Date:  1984-10       Impact factor: 3.441

7.  Class specificity of naturally acquired and vaccine-induced antibody to type III group B streptococcal capsular polysaccharide: determination with a radioimmunoprecipitin assay.

Authors:  M S Edwards; P A Fuselier; M A Rench; D L Kasper; C J Baker
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

8.  Murine monoclonal antibodies to type Ib polysaccharide of group B streptococci bind to human milk oligosaccharides.

Authors:  D G Pritchard; B M Gray; M L Egan
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

9.  Expression of the murine interleukin-4 gene in an attenuated aroA strain of Salmonella typhimurium: persistence and immune response in BALB/c mice and susceptibility to macrophage killing.

Authors:  K Denich; P Börlin; P D O'Hanley; M Howard; A W Heath
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

10.  Isotype composition of antibodies to streptococcus group B type III polysaccharide and to tetanus toxoid in maternal, cord blood sera and in breast milk.

Authors:  T Lagergård; K Thiringer; L Wassén; R Schneerson; B Trollfors
Journal:  Eur J Pediatr       Date:  1992-02       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.